Former US Attorney General to be Counsel for Cannabis Company

Cannabis Investing News
CSE:ACRG.U

Whitaker, along with his law firm, Graves Garrett, will coordinate legal matters and develop a legal strategy for the company as it expands.

Matthew Whitaker, former acting US attorney general, has joined the marijuana industry, working as an outside counsel to Ontario-based Alternate Health (CSE:AHG,OTCQB:AHGIF).

Alternate Health is a hemp-derived cannabidiol (CBD) producer developing a variety of branded products. The company confirmed on Tuesday (August 27) that Whitaker, along with his law firm, Graves Garrett, will coordinate legal matters and develop a legal strategy for the company as it expands.

Whitaker served as the acting attorney general of the US from November 2018 until February 2019, when US President Donald Trump nominated William Barr to fill the position, replacing Whitaker. Prior to that, he served as the US attorney for the Southern District of Iowa.

In a press release, Whitaker said he is looking forward to the challenge of advising Alternate Health’s management team.

“I think there is serious potential in the CBD industry, and everyone at Alternate Health will work hard to be a leader in the industry,” Whitaker added.

In the announcement, company president Dr. Robert Blaine said it is “essential” that Alternate Health stay ahead of the curve as the legal environment surrounding CBD changes with new government and FDA regulations.

“We believe (Whitaker’s) experience in government and the Department of Justice is a significant asset as we move forward,” Blaine said.

The former attorney general will also be tasked with leading the company’s efforts to investigate the actions of a California-based competitor in Canada.

Scott Holtby, vice president of communications for Alternate Health, told the Investing News Network (INN) he cannot divulge any details about the investigation.

The press release also says that Alternate Health will be divesting its cannabis assets and focusing completely on hemp-derived CBD.

This decision follows in the footsteps of an announcement in May that indicated the company would be refocusing its assets towards the booming hemp-derived CBD industry in the US.

Holtby added that, due to the illegal status of cannabis and the passing of the farm bill last year, which legalized the production of hemp and its derivatives, the CBD market currently has great potential.

“The way we see the next couple of years is that, due to the legal environment surrounding (marijuana), we think the most amount of opportunity for our products and our system will be in CBD,” he told INN.

Recently, Whitaker and his firm also became outside counsel for PC Matic, a cybersecurity company, and Whitaker is now managing director of political consultancy Clout Public, a division of Axiom Strategies.

Whitaker’s months-long stint as head of the US Department of Justice was undercut with judgment for close business ties with Trump and criticism of the investigation into Russian interference in Trump’s rise to the presidency.

Whitaker isn’t the only high-profile politician to enter the cannabis space. Former House Speaker John Boehner joined the advisory board of Acreage Holdings (CSE:ACRG.U,OTCQX:ACRGF) last year.

Alternate Health generated C$1.9 million in revenue during its Q2 2019 earnings season.

The company’s share price opened at C$0.17 on Tuesday before rising to C$0.18, its high of the day, and then dropping back to its opening price. As of 2:39 p.m. EDT, it had dropped by 2.86 percent.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: Acreage Holdings is a client of the Investing News Network. This article is not paid-for content. 

The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

The Conversation (0)
×